DHAP plus filgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory lymphoma: A single center experience

Transfus Apher Sci. 2016 Feb;54(1):48-52. doi: 10.1016/j.transci.2016.01.012. Epub 2016 Jan 12.

Abstract

This study aimed to evaluate the efficiency of DHAP regimen plus filgrastim for mobilization of stem cells in patients with recurrent and/or refractory lymphoma. Thirty-four patients who took DHAP as salvage therapy prior to autologous stem cell transplantation were included. After chemotherapies, 2 cycles of DHAP plus filgrastim were administered to the patients. Stem cells from 32 patients (94%) were collected on median 11th day (8-12), and the median collected CD34(+) cell dose was 9.7 × 10(6)/kg (range 3.8-41.6). DHAP plus filgrastim was found to be an effective chemotherapy regimen in mobilizing CD34(+) stem cells into the peripheral.

Keywords: DHAP plus filgrastim; Lymphoma; Stem cell mobilization.

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cisplatin / therapeutic use
  • Cytarabine / therapeutic use
  • Dexamethasone / therapeutic use
  • Female
  • Filgrastim / therapeutic use*
  • Hematopoietic Stem Cell Mobilization*
  • Hematopoietic Stem Cell Transplantation*
  • Hodgkin Disease / therapy
  • Humans
  • Lymphoma / drug therapy
  • Lymphoma / therapy*
  • Lymphoma, Non-Hodgkin / therapy
  • Male
  • Recurrence
  • Transplantation, Autologous

Substances

  • Cytarabine
  • Dexamethasone
  • Filgrastim
  • Cisplatin

Supplementary concepts

  • DHAP protocol